The Generic Cliff Isn’t a Moment—it’s a Deadline.
In pharma, “expiration” sounds like a single date on a calendar. In reality, it’s a countdown that starts years earlier—often long before anyone outside the industry can see the finish line.
A recen…

Patent thickets are the new moat—and they’re getting bigger.
If you’ve ever wondered why some blockbuster biologics seem to “stay expensive” long after their original patents should have expired, the answer is often not one patent. It’s many—layered,…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you deal with after you’ve already committed—after the acquisition, after the licensing spend, after the clinical roadmap is locked in.
Bu…

Most teams look at drug patents the wrong way.
They read claims. They track expiration dates. They wait for the next “Orange Book” update.
But in formulation patents—the ones that govern how a drug is made, stabilized, delivered, absorbed, or prote…

Russia’s VED and SSM lists aren’t just bureaucratic paperwork—they’re timing tools. And for generic manufacturers, timing is everything.
Here’s the agitation: in markets where reimbursement and procurement are tightly linked to government lists, “launc…

Pharma pipelines don’t fail because of science. They fail because of risk.
That’s the uncomfortable truth behind Freedom-to-Operate (FTO): it’s not a regulatory checkbox—it’s a business survival tool.
In an industry where a single patent can delay laun…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Competitive Moat
In generic drug land, the default strategy is often binary: file an ANDA, win on price, and hope the market does the rest. But that playbook is getting harder to sustain a…

Pharma IP teams: Russia’s patent-term extension rules just got harder to ignore. Here’s what to know right now.
If your company files in Russia—or relies on Russian exclusivity to protect revenue—this is the moment to stop treating patent-term extensio…

Drug patent portfolios are often treated like static assets—filed, granted, and then quietly shelved. But in today’s litigation-aware landscape, that mindset is increasingly expensive. The real competitive edge comes from designing your patent strategy…

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical supply chain, “patent expiration” is often treated like background noise: something to monitor, maybe, when it becomes unavoidable. But the reality i…